Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
143 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | recruiting | Phase 2 / Phase 3 | 626 | Mirati Therapeutics Inc.INDUSTRY | 47 | Sep 16, 2026 | clinicaltrials |
| NCT07811193 | A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum | recruiting | Phase 2 | 140 | Vividion Therapeutics, Inc.INDUSTRY | 22 |
| Sep 16, 2026 |
| clinicaltrials |
| NCT07087054 | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen(CAREFNDR) | recruiting | Phase 3 | 141 | Crinetics Pharmaceuticals Inc.INDUSTRY | 14 | Sep 15, 2026 | clinicaltrials |
| NCT04575935 | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | recruiting | Phase 3 | 580 | M.D. Anderson Cancer CenterOTHER | 5 | Sep 14, 2026 | clinicaltrials |
| NCT06724237 | Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | recruiting | Phase 3 | 294 | Eastern Cooperative Oncology GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT07539844 | Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries(ConFeR) | recruiting | — | 1,000 | AbbVieINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT06119581 | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer(SUNRAY-01) | recruiting | Phase 3 | 1,264 | Eli Lilly and CompanyINDUSTRY | 29 | Sep 8, 2026 | clinicaltrials |
| NCT07192991 | Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America(NECTARINE) | recruiting | — | 200 | Latin American Cooperative Oncology GroupOTHER | 4 | Sep 8, 2026 | clinicaltrials |
| NCT07361497 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | recruiting | Phase 3 | 850 | Bristol-Myers SquibbINDUSTRY | 32 | Sep 8, 2026 | clinicaltrials |
| NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | recruiting | Phase 3 | 750 | Bristol-Myers SquibbINDUSTRY | 36 | Sep 8, 2026 | clinicaltrials |
| NCT07405801 | A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer | recruiting | Phase 2 | 80 | Hoffmann-La RocheINDUSTRY | 12 | Sep 8, 2026 | clinicaltrials |
| NCT01949129 | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia | recruiting | Phase 2 / Phase 3 | 1,800 | St. Anna KinderkrebsforschungOTHER | 31 | Sep 4, 2026 | clinicaltrials |
| NCT07368998 | To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer(optINAVO) | recruiting | Phase 2 | 80 | Hoffmann-La RocheINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)(OMAHA-003) | recruiting | Phase 3 | 1,310 | Merck Sharp & Dohme LLCINDUSTRY | 36 | Sep 3, 2026 | clinicaltrials |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301) | recruiting | Phase 3 | 450 | AmgenINDUSTRY | 35 | Sep 3, 2026 | clinicaltrials |
| NCT07287150 | A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer(InavoPC) | recruiting | Phase 2 | 100 | Hoffmann-La RocheINDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT05862285 | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study(UmbrellaMAX) | recruiting | Phase 3 | 100 | Hoffmann-La RocheINDUSTRY | 15 | Sep 2, 2026 | clinicaltrials |
| NCT06079671 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)(eVOLVECervical) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 19 | Aug 25, 2026 | clinicaltrials |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC(ALKAZAR) | recruiting | Phase 3 | 450 | Nuvalent Inc.INDUSTRY | 29 | Aug 25, 2026 | clinicaltrials |
| NCT05020236 | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments(MAGNETISMM-5) | recruiting | Phase 3 | 893 | PfizerINDUSTRY | 26 | Aug 24, 2026 | clinicaltrials |
| NCT05899608 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | recruiting | Phase 3 | 1,600 | Summit TherapeuticsINDUSTRY | 17 | Aug 24, 2026 | clinicaltrials |
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy(CAMBRIA-1) | recruiting | Phase 3 | 4,300 | AstraZenecaINDUSTRY | 39 | Aug 19, 2026 | clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT06330064 | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) | recruiting | Phase 1 / Phase 2 | 680 | Daiichi SankyoINDUSTRY | 18 | Aug 5, 2026 | clinicaltrials |
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) | recruiting | Phase 1 / Phase 2 | 451 | GlaxoSmithKlineINDUSTRY | 19 | Aug 3, 2026 | clinicaltrials |
| NCT07225309 | A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer | recruiting | N/A | 300 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Aug 3, 2026 | clinicaltrials |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)(LITESPARK-033) | recruiting | Phase 3 | 904 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Aug 3, 2026 | clinicaltrials |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 30 | Jul 31, 2026 | clinicaltrials |
| NCT07039916 | Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | recruiting | Phase 3 | 231 | Immunovant Sciences GmbHINDUSTRY | 15 | Jul 30, 2026 | clinicaltrials |
| NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | recruiting | Phase 3 | 199 | Janssen Research & Development, LLCINDUSTRY | 17 | Jul 27, 2026 | clinicaltrials |
| NCT06592924 | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response(TRIPLE-SWITCH) | recruiting | Phase 3 | 830 | Canadian Cancer Trials GroupNETWORK | 4 | Jul 14, 2026 | clinicaltrials |
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | recruiting | Phase 1 / Phase 2 | 305 | GlaxoSmithKlineINDUSTRY | 23 | Jul 7, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT04185935 | Molecular Genetics Studies of Cancer Patients and Their Relatives | recruiting | — | 999,999 | City of Hope Medical CenterOTHER | 5 | Jun 29, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
| NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | recruiting | Phase 3 | 1,180 | Celcuity IncINDUSTRY | 22 | May 18, 2026 | clinicaltrials |
| NCT04871542 | Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | recruiting | — | 2,062 | SWOG Cancer Research NetworkNETWORK | 5 | May 5, 2026 | clinicaltrials |
| NCT05445791 | Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations(METLUNG) | recruiting | Phase 3 | 312 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05852990 | Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC | recruiting | Phase 3 | 28 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06238882 | Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. | recruiting | N/A | 74 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT02978521 | Pulmonary Rehabilitation in Advanced Non-small Cell Lung Cancer Patients | recruiting | N/A | 94 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 8, 2026 | clinicaltrials |
Data updated 14 days agoSource updated unknownsource: clinicaltrials